
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TPT0201
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Tetra Pharm Technologies
Deal Size : Undisclosed
Deal Type : Collaboration
Tetra Pharm and Glysious Partner to Develop Transdermal Endocannabinoid System Drugs
Details : The collaboration aims to revolutionize transdermal release of difficult-to-formulate compounds, including TPT0201, studied for mild cognitive impairment, targeting the endocannabinoid system.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 24, 2024
Lead Product(s) : TPT0201
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Tetra Pharm Technologies
Deal Size : Undisclosed
Deal Type : Collaboration
